Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68(6):394–424. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Honma Y, Nagashima K, Hirano H, Shoji H, Iwasa S, Takashima A, Okita N, Kato K, Boku N, Murakami N, et al. 2020. Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy. Cancer Med. 9(2):595–604. DOI:10.1002/cam4.2708
   PubMed Web of Science ®Google Scholar
• Kikuchi Y, Shimada H, Yamaguchi K, Igarashi Y. 2019. Systematic review of case reports of Japanese esophageal neuroendocrine cell carcinoma in the Japanese literature. Int Cancer Conf J. 8(2):47–57. doi:10.1007/s13691-019-00359-5.
   PubMed Web of Science ®Google Scholar
• Barsouk A, Rawla P, Hadjinicolaou AV, Aluru JS, Barsouk A. 2019. Targeted therapies and immunotherapies in the treatment of esophageal cancers. Med Sci (Basel). 7(10):100. doi:100.doi:10.3390/medsci7100100.
   Google Scholar
• Markham A, Keam SJ. 2019. Camrelizumab: first global approval. Drugs. 79(12):1355–1361. doi:10.1007/s40265-019-01167-0.
   PubMed Web of Science ®Google Scholar
• Lickliter JD, Gan HK, Voskoboynik M, Arulananda S, Gao B, Nagrial A, Grimison P, Harrison M, Zou J, Zhang L, et al. 2020. A first-in-human dose finding study of camrelizumab in patients with advanced or metastatic cancer in Australia. Drug Des Devel Ther. 14:1177–1189. doi:10.2147/DDDT.S243787.
   PubMed Web of Science ®Google Scholar
• Rice TW, Ishwaran H, Ferguson MK, Blackstone EH, Goldstraw P. 2017. Cancer of the esophagus and esophagogastric junction: an eighth edition staging primer. J Thorac Oncol. 12(1):36–42. doi:10.1016/j.jtho.2016.10.016.
   PubMed Web of Science ®Google Scholar
• Giannetta E, Guarnotta V, Rota F, de Cicco F, Grillo F, Colao A, Nike FA. 2019. A rare rarity: neuroendocrine tumor of the esophagus. Crit Rev Oncol Hematol. 1373:92–107. doi:10.1016/j.critrevonc.2019.02.012.
   Google Scholar
• Liu T, Ding S, Dang J, Wang H, Chen J, Li G. 2019. Elective nodal irradiation versus involved-field irradiation in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a network meta-analysis. Radiat Oncol. 14(1):176. doi:10.1186/s13014-019-1388-8.
   PubMed Web of Science ®Google Scholar
• Jing SW, Qin JJ, Liu Q, Zhai C, Wu YJ, Cheng YJ, Czito BG, Wang J. 2019. Comparison of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for esophageal cancer: a meta-analysis. Future Oncol. 15(20):2413–2422. doi:10.2217/fon-2019-0024.
   PubMed Web of Science ®Google Scholar
• Janmaat VT, Steyerberg EW, van der Gaast A, Mathijssen RH, Bruno MJ, Peppelenbosch MP, Kuipers EJ, Spaander MC. 2017. Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer. Cochrane Database Syst Rev. 11:CD004063. doi:10.1002/14651858.CD004063.pub4.
   PubMedGoogle Scholar
• Deng HY, Li G, Luo J, Li XR, Alai G, Lin YD. 2018. The role of surgery in treating resectable limited disease of esophageal neuroendocrine carcinoma. World J Surg. 42(8):2428–2436. doi:10.1007/s00268-018-4475-3.
   PubMed Web of Science ®Google Scholar
• Sudarshan M. 2019. Locoregional and oligometastatic recurrence of esophageal cancer-what are the management strategies? J Thorac Dis. 11(S13):S1643–S1645. doi:10.21037/jtd.2019.06.76.
   PubMedGoogle Scholar
• Yuan X, Lv J, Dong H, Wang J. 2017. Does cervical lymph node recurrence after oesophagectomy or definitive chemoradiotherapy for thoracic oesophageal squamous cell carcinoma benefit from salvage treatment? Interact Cardiovasc Thorac Surg. 24(5):792–795. doi:10.1093/icvts/ivw441.
   PubMed Web of Science ®Google Scholar
• Wang Z, Lin S, Wang F, Liu S. 2019. Salvage lymphadenectomy for isolated cervical lymph node recurrence after curative resection of thoracic esophageal squamous cell carcinoma. Ann Transl Med. 7(11):238. doi:10.21037/atm.2019.04.64.
   PubMed Web of Science ®Google Scholar
• Du D, Song T, Liang X, Fang M, Wu S. 2017. Concurrent chemoradiotherapy with elective lymph node irradiation for esophageal cancer: a systemic review and pooled analysis of the literature. Dis Esophagus. 30:1–9. doi:10.1111/dote.12471.
   Web of Science ®Google Scholar
• Li Q, Zhu S, Li S, Deng W. 2019. Elective nodal irradiation provides a superior therapeutic modality for lymph node positivity esophageal squamous cell carcinoma patients receiving definitive radiotherapy versus involved-field irradiation. Medicine (Baltimore). 98(3):e14080. doi:10.1097/MD.0000000000014080.
   PubMed Web of Science ®Google Scholar
• Mo H, Huang J, Xu J, Chen X, Wu D, Qu D, Wang X, Lan B, Wang X, Xu J, et al. 2018. Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. Br J Cancer. 119(5):538–545. DOI:10.1038/s41416-018-0100-3
   PubMed Web of Science ®Google Scholar
• Huang J, Xu B, Mo H, Zhang W, Chen X, Wu D, Qu D, Wang X, Lan B, Yang B, et al. 2018. Safety, activity, and biomarkers of SHR-1210, an Anti-PD-1 antibody, for patients with advanced esophageal carcinoma. Clin Cancer Res. 24(6):1296–1304. DOI:10.1158/1078-0432.CCR-17-2439
   PubMed Web of Science ®Google Scholar
• Huang J, Mo H, Zhang W, Chen X, Qu D, Wang X, Wu D, Wang X, Lan B, Yang B, et al. 2019. Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China. Cancer. 125(5):742–749. DOI:10.1002/cncr.31855
   PubMed Web of Science ®Google Scholar
• Xu J, Zhang Y, Jia R, Yue C, Chang L, Liu R, Zhang G, Zhao C, Zhang Y, Chen C, et al. 2019. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study. Clin Cancer Res. 25(2):515–523. DOI:10.1158/1078-0432.CCR-18-2484
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang B, Chen X, Mo H, Wu D, Lan B, Li Q, Xu B, Huang J. 2019. Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody. Thorac Cancer. 10:1395–1401. doi:10.1111/1759-7714.13083.
   PubMed Web of Science ®Google Scholar
• Zhang B, Qi L, Wang X, Jiang J, Zhang X, Liu Y, Mu L, Huang J. Phase 2 study of camrelizumab (anti-PD-1 antibody) combined with apatinib and chemotherapy for the first-line treatment of advanced esophageal squamous cell carcinoma. J Clin Oncol. 2019;37(15_suppl):4033. doi:10.1200/JCO.2019.37.15_suppl.4033.
   Web of Science ®Google Scholar
• Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, Chen J, Zhang H, Niu Z, Fan Q, et al. 2020. Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 21(6):832–842. DOI:10.1016/S1470-2045(20)30110-8
   PubMed Web of Science ®Google Scholar
• Wang W, Wu M, Liu M, Yan Z, Wang G, Mao D, Wang M. 2020. Hyperprogression to camrelizumab in a patient with esophageal squamous cell carcinoma harboring EGFR kinase domain duplication. J Immunother Cancer. 8(1):e000793. doi:10.1136/jitc-2020-000793.
   PubMed Web of Science ®Google Scholar
• Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. 2018. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 15:325–340. doi:10.1038/nrclinonc.2018.29.
   PubMed Web of Science ®Google Scholar
• Zhao S, Ren S, Jiang T, Zhu B, Li X, Zhao C, Jia Y, Shi J, Zhang L, Liu X, et al. 2019. Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer. Cancer Immunol Res. 7:630–643. doi:10.1158/2326-6066.CIR-17-0640.
   PubMed Web of Science ®Google Scholar
• Liang L, Wen Y, Hu R, Wang L, Xia Y, Hu C, Qiao Y, Geng X, Chen T, Fei J, et al. 2019. Safety and efficacy of PD-1 blockade-activated multiple antigen-specific cellular therapy alone or in combination with apatinib in patients with advanced solid tumors: a pooled analysis of two prospective trials. Cancer Immunol Immunother. 68:1467–1477. doi:10.1007/s00262-019-02375-z.
   PubMed Web of Science ®Google Scholar
• Butters O, Young K, Cunningham D, Chau I, Starling N. 2019. Targeting vascular endothelial growth factor in oesophagogastric cancer: a review of progress to date and immunotherapy combination strategies. Front Oncol. 9:618. doi:10.3389/fonc.2019.00618.
   PubMed Web of Science ®Google Scholar
• Jennings JJ, Mandaliya R, Nakshabandi A, Lewis JH. 2019. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies. Expert Opin Drug Metab Toxicol. 15(3):231–244. doi:10.1080/17425255.2019.1574744.
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD. 2018. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 378:158–168. doi:10.1056/NEJMra1703481.
   PubMed Web of Science ®Google Scholar